radiation
Search documents
X @Elon Musk
Elon Musk· 2026-03-19 19:22
RT Sawyer Merritt (@SawyerMerritt)Nvidia CEO Jensen Huang in new interview on orbital datacenters:"The challenge of course is that cooling, you can't take advantage of conduction and convection, so you can only use radiation, and radiation requires very large surfaces, but that's not an impossible things to solve. There's a lot of space in space. We're going to go explore it. We're already radiation hardened. We have Cuda in satellites around the world. In the meantime, we're going to explore what is the ar ...
Theralase(R) Investor Conference Call Reminder
Newsfile· 2025-11-17 12:00
Core Viewpoint - Theralase Technologies Inc. is hosting a conference call on November 19, 2025, to update investors on the interim data from its Phase II clinical study for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer, along with financial and operational results for Q3 2025 [1][3]. Study II Update - As of November 7, 2025, Theralase is on track to complete enrollment in Q4 2025, with data lock and regulatory submissions expected in Q1 2027 [3]. - 88 patients have been treated, representing 97.8% of the targeted enrollment of 90 patients [6]. - 64.3% (54 out of 84) of patients achieved a Complete Response (CR) at any point, while 72.6% (61 out of 84) achieved a Total Response (TR) [6]. - At the 450-day assessment, 40% (18 out of 45) maintained a CR, and 42.2% (19 out of 45) maintained a TR, indicating durability of response [6]. Financial Update - Revenue decreased by 5% to $590,573 from $622,984, while the cost of sales decreased by 10% to $299,743, representing 51% of revenue [14]. - Gross margin remained stable at $290,830, which is 49% of revenue [14]. - Selling expenses decreased by 18% to $212,421, while administrative expenses increased by 12% to $1,444,687 [14]. - Research and development expenses increased by 1% to $2,116,540, reflecting increased activity for Study II [14]. - The net loss increased by 3% to $3,435,145, including $708,521 in non-cash expenses [14]. - The company raised $672,627 via a non-brokered private placement and has $280,000 in outstanding short-term loans at 15% interest as of November 7, 2025 [14].